336 related articles for article (PubMed ID: 16856881)
21. MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas.
Liggins AP; Cooper CD; Lawrie CH; Brown PJ; Collins GP; Hatton CS; Pulford K; Banham AH
Br J Haematol; 2007 Aug; 138(4):479-86. PubMed ID: 17608765
[TBL] [Abstract][Full Text] [Related]
22. Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival.
Yoshioka T; Miura I; Kume M; Takahashi N; Okamoto M; Ichinohasama R; Yoshino T; Yamaguchi M; Hirokawa M; Sawada K; Nakamura S
Genes Chromosomes Cancer; 2005 Feb; 42(2):149-57. PubMed ID: 15543600
[TBL] [Abstract][Full Text] [Related]
23. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
24. Data pattern analysis for the individualised pretherapeutic identification of high-risk diffuse large B-cell lymphoma (DLBCL) patients by cytomics.
Valet GK; Hoeffkes HG
Cytometry A; 2004 Jun; 59(2):232-6. PubMed ID: 15170602
[TBL] [Abstract][Full Text] [Related]
25. Prognostic biomarkers in diffuse large B-cell lymphoma.
Lossos IS; Morgensztern D
J Clin Oncol; 2006 Feb; 24(6):995-1007. PubMed ID: 16418498
[TBL] [Abstract][Full Text] [Related]
26. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
Bavi P; Abubaker J; Hussain A; Sultana M; Al-Dayel F; Uddin S; Al-Kuraya KS
Hum Pathol; 2008 Jun; 39(6):885-94. PubMed ID: 18400256
[TBL] [Abstract][Full Text] [Related]
27. Gene expression profiling of diffuse large B-cell lymphoma supervised by CD21 expression.
Miyazaki K; Yamaguchi M; Suguro M; Choi W; Ji Y; Xiao L; Zhang W; Ogawa S; Katayama N; Shiku H; Kobayashi T
Br J Haematol; 2008 Aug; 142(4):562-70. PubMed ID: 18537973
[TBL] [Abstract][Full Text] [Related]
28. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
Le Gouill S; Talmant P; Touzeau C; Moreau A; Garand R; Juge-Morineau N; Gaillard F; Gastinne T; Milpied N; Moreau P; Harousseau JL; Avet-Loiseau H
Haematologica; 2007 Oct; 92(10):1335-42. PubMed ID: 18024371
[TBL] [Abstract][Full Text] [Related]
29. Logical analysis of diffuse large B-cell lymphomas.
Alexe G; Alexe S; Axelrod DE; Hammer PL; Weissmann D
Artif Intell Med; 2005 Jul; 34(3):235-67. PubMed ID: 16023562
[TBL] [Abstract][Full Text] [Related]
30. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
Banham AH; Connors JM; Brown PJ; Cordell JL; Ott G; Sreenivasan G; Farinha P; Horsman DE; Gascoyne RD
Clin Cancer Res; 2005 Feb; 11(3):1065-72. PubMed ID: 15709173
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of clonal diversity of immunoglobulin gene rearrangements in patients with diffuse large B-cell lymphoma.
Yang MH; Yen CC; Chiang SC; Bai LY; Lee KD; Hsiao LT; Chao TC; Wang WS; Liu JH; Chiou TJ; Chen PM
Oncol Rep; 2005 Mar; 13(3):503-8. PubMed ID: 15706425
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of immunohistochemistry in identification of prognostically important subgroups (GCB and ABC) in a heterogeneous group of diffuse large B-cell lymphomas--a review article.
Jabłońska J; Jesionek-Kupnicka D
Pol J Pathol; 2008; 59(3):121-7. PubMed ID: 19097355
[TBL] [Abstract][Full Text] [Related]
33. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.
Booman M; Szuhai K; Rosenwald A; Hartmann E; Kluin-Nelemans H; de Jong D; Schuuring E; Kluin P
J Pathol; 2008 Oct; 216(2):209-17. PubMed ID: 18729069
[TBL] [Abstract][Full Text] [Related]
34. [Detection for subtype-specific genomic/genetic alterations in diffuse large B-cell lymphoma (DLBCL)].
Tagawa H
Rinsho Ketsueki; 2008 Feb; 49(2):73-81. PubMed ID: 18341036
[No Abstract] [Full Text] [Related]
35. Microarray gene expression data with linked survival phenotypes: diffuse large-B-cell lymphoma revisited.
Segal MR
Biostatistics; 2006 Apr; 7(2):268-85. PubMed ID: 16284340
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression.
Miyazaki K; Yamaguchi M; Imai H; Kobayashi K; Tamaru S; Kobayashi T; Shiku H; Katayama N
Int J Hematol; 2015 Aug; 102(2):188-94. PubMed ID: 26009281
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic changes and their clinical relevance in Saudi diffuse large B-cell lymphoma. A molecular and tissue microarray analysis of 100 cases.
Al-Kuraya KS; Siraj AK; Al-Dayel FA; Ezzat AA; Al-Jommah NA; Atizado VL; Narayanappa RN
Saudi Med J; 2005 Jul; 26(7):1099-103. PubMed ID: 16047061
[TBL] [Abstract][Full Text] [Related]
38. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.
Lossos IS; Czerwinski DK; Alizadeh AA; Wechser MA; Tibshirani R; Botstein D; Levy R
N Engl J Med; 2004 Apr; 350(18):1828-37. PubMed ID: 15115829
[TBL] [Abstract][Full Text] [Related]
39. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
[TBL] [Abstract][Full Text] [Related]
40. Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas.
Ramuz O; Bouabdallah R; Devilard E; Borie N; Groulet-Martinec A; Bardou VJ; Brousset P; Bertucci F; Birg F; Birnbaum D; Xerri L
Int J Oncol; 2005 Jan; 26(1):151-7. PubMed ID: 15586235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
